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The Intravenous Streptokinase in Acute Myocardial Infarction
(I .S.A .M .I trial was a prospective, placebo-controlled, double.
blind multicenter trial of high-dose short-term intravenous strep-
tokinase in acute myocardial infarction administered within 6 h
after the onset of symptoms
. Global and regional left ventricular
election fractions were determined by radionuclide venlriculogra-
pbs' In a subset of 120 patients 3 days, 4 weeks, 7 months, IS
months and 3 years after acute myocardial infarction .
In patients with anterior myocardial infarction, left ventricular
ejection fraction was higher in the streptokinase than in the
placebo group 3 days after acute infarction (49 ± 14% vs . 40 ±
11 %, p = 0
.021 . This difference of about 10% units in ejection
fraction persisted during the 3 year follow-up period
. Among
streptokinase-treated patients, regional left ventrkmlar ejection
Acute myocardial infarction is mostly caused by a throm-
hotic occlusion of a coronary artery (1 .2). Argiographic
studies demonstrated that intravenous strepto'cinase can
reopen coronary arteries occluded by a throb bus 13,4) .
Intravenous administration I,f streptokinase is m_refore an
effective way to salvage jeopardized myocardium and to
limit infarct size (3 .4). Accordingly, large placebo-controlled
trials (5-7) comparing the effects of intravenous streptoki-
nase with conventional treatment demonstrated a reduction
in mortality, especially in patients with anterior myocardial
infarction . Left ventricular function is a powerful predictor
of long-term prognosis after myocardial infarction (8-10)
.
Previous studies (11-13) of intravenous streptokinase as-
sessed left ventricular function only within the Ist year after
acute myocardial infarction .
In the present study we determined global and regional
left ventricular function by radionuclide ventriculography up
to 3 years after acute myocardial infarction in a subset of
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fraction was higher within the infarct zone as well as in remote
myocardium throughout the follow-up period . Among patients
with inferior infarction, no significant differences between the
treatment and control groups were demonstrable with respect to
global and regional left ventricular ejection fraction,
Thus, Intravenous administration of streptokinase within 6 h
after the onset of symptoms of acute myocardial infarction pre-
serves left ventricular I, ction over a period of ?3 years in
patients with acute anterior myocardial infarction
. II improves
regional myocardial function within the Infarct zone as well as in
remote areas. In patient- with acute inferior myocardial infarc-
tion, benefit from intro eeous streptokinase is of only minor
degree.
(J Am Coll Cardiol 1991 ;18:1610-6)
patients from the Intravenous Streptokinase in Acute Myo-
cardial Infarction (LS.A .M .) trial .
Methods
Study patients . The I .S .A .M . trial was a prospective,
placebo-controlled, double-blind multicenter trial investigat-
ing the effects of high dose short-term intravenous streptoki-
nase in acute myocardial infarction versus treatment with
heparin and aspirin only (14) . The primary study end point
was a comparison of mortality 21 days after infarction in
streptokinase- and placebo-treated patients . From March
1982 to March 1985 . 1,741 subjects aged up to 75 years
participated
. The study design has been published in detail
elsewhere (14). In brief, patients were included if they could
be treated with the study medication within 6 h after the
onset of acute myocardial infarction and had no contraindi-
cation to streptokinase therapy . Criteria for evolving ,'cute
myocardial infarction wc ,e typ:cai clinical syarpimns with
electrocardiographic ST segment elevations al mm in the
limb leads and y2 mm in the chest leads, or both . Informed
consent was obtained from all patients inch
:ded . The study
was approved by an independent ethical and review com-
mittee .
After randomization, heparin (5,930 Ill) . aspirin (0.5 g)
pv5.l,O'1i,5y.5a
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and methylprednisolone 10.25 €I were given intravenously .
followed by administration of the study medication, a 611 min
infusion of 1 .5 million IU of streptokinase or placebo .
Treatment was continued with heparin 1800 to I .(M I U .S
I
for 3 to 4 days followed by phenprocoumon for >_3 neck, .
In all patients, blood samples were drawn every 2 h for
the 1st 30 h and every 4 h for the nest 20 h to determine
creatine kinase myocardial isoenzyme levels (14) . Time-
activity curves of creatine kinase were evaluated concerning
time to peak activity after the start of Ireatment to estimate
maintenance or early restoration of coronary blood flow . By
comparing enzyme release data (14) and angiographically
documented rates of reperfusion 11 .3,41, a threshold vulo: of
<<<II hours from the start of treatment to peak activit,, of
creatine kinase was chosen as an indicator of maintenance or
early restoration of coronary blood flow .
Radionuclide rentriculography . In the subset of 120 pa-
tients initially treated at our institution, left ventricular
function was assessed by gated equilibrium radionuclide
ventricelogmphy 3 days . 4 weeks . 7 months . 18 months and
3 years after acute myocardial Infarcl?on . Radionuclide
ventriculography was performed after in vivo labeling of
autologous red blood cells with 740 MBq (1 (1 mCi) of
technetium-99m 115) by using a small field of view Anger
camera with a low energy all-purpose parallel hole collimator
and a dedicated computer system IIMAC 7300. CGR Koch
& Sterzell . Data acquisition was performed in anterior and
"best septaf- left anterior oblique projections . Each acqui-
sition (5 to 10 min .) consisted of 16 frames spanning 90Si of
the cardiac cycles . Global left ventricular ejection fraction
was calculated with a semiautomatic program based on the
isocount-line concept using end-diastolic and end-.systolic
regions of interest and a left posteroapical region of interest
for background correction (16 .17) . Regional left ventricular
ejection fraction was calculated by dividing end-diastolic and
end-systolic regions of interest into angular sectors of -15'
each 112,171 . Anterolateral . apical ant, inferior walls (five
sectors) were analyzed in anterior projection, and septa) .
apical and posterolateral walls (-eight sectors( in left anterior
oblique projection . Normal values and data concerning
accuracy and reproducibility of these methods have been
published in detail elsewhere 116,17).
Statistical analysis
. Data arc presented as mean values
SD . Contingency tables were evaluated with use of chi-
square analysis, ordered variables by the Mann-Whitney
two sample rank test . Multiple comparisons for intraindivid-
ual analysis of ejection fraction data were performed accord-
ing to the distribution-free technique of Wilcoxon and
Wilcox (18) . Two-sided probability values are reported .
Results
Clinical characteristics (Table 1)
. Of the 120 patients
included in the present stud} . 60 had been assigned to the
streptokinase and 60 to the placebo group. The distribution
of selected characteristic, at baseline . during the 4 week
VOTH ET AL .
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hospital period and during the 3 year follow-up period is
presented in Table I
. With the exception of time from the
start of treatment to peak creative kinase activity- basehae
characteristics were distributed homogeneously between the
two groups . Further analysis based on the partitioning of
chi-square contingency tables revealed that the inhomoge-
neity in time to peak activity of creatine kinase must be
attributed to the higher frequency of early reperfusion in the
streptokinase group compared with the placebo group (time
to peak activity of creatine kinase
V
I I h vs . >I I h after the
start of treatment, p = 11 .1012). During the 4 week hospital
period and during the 3 year follow-up period, the frequency
of reinfaretion . coronary bypass surgery and coronary an-
gioplasty was low in both groups and did not differ between
groups .
Global left renlricular function (fable 21
. Three days
after acute myocardial infarction, left ventricular ejection
fraction was reduced in both the streptokinase and the
placebo groups (p < 0 .001 . respectively) compared with
normal values from our laboratory 165
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Table 2 . Left Ventricular Ejection Fraction From 3 Days to 3
Years After Acute 67yocerdial Infarction in Streptokinase- and
Placebo-Treeled Recess
AMI and 1671 = anterior and inferior myocardial iniarction. respectively:
LVEF = tall vent ocular ejection fraction : 11_p > 0.10
.
group, a difference of 6% ejection fraction units (p = 0 .04)
was observed between streptokinase-treated and control
patients . When the two groups were subdivided on the basis
of infarct location, left ventricular ejection fraction was
higher in the streptokinase group only in patients with
anterior myocardial infarction (p = 0.02) . In both treatment
groups. especially in the placebo group, left ventricular
ejection fraction was lower in patients with anterior than in
those with inferior infarction (p = 0 .03 streptokinase . p <
0 .001 placebo group) .
Results similar to those of the initial investigation were
obtained in follow-up radionuclide ventriculography 4
weeks, 7 months, Ig months and 3 years after acute myo-
cardial infarction (Table 2)
. In all investigations . left ventric-
ular ejection fraction was between 5% to 0% units higher in
the streptokinase than in the placebo group
. This difference
was predominantly caused by a respective difference of 9%
to 12% units in patients with anterior myocardial infarction
.
Among patients with inferior myocardial iaferc ;ioa, differ-
ences between the treatment and control groups in all
investigations were only 0% to 4% units (p > 0 .25).
In a subgroup of 75 patients (35 in the streptokinase and
40 in the placebo group), all five radionuclide determinations
of left ventricular ejection fraction (i .e. . complete follow-up)
were available for the study of the development of left
ventricular function within individual patients
. With the
exception of deaths (0%, p < 0 .001), the characteristics
displayed in Table I did not differ between this subgroup and
patients with incomplete follow-up
. Aside from death, the
major reason for incomplete follow-up was patient refusal
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Figure 1 . Left ventricular function (mean values ± SEMI from 3
days up to 3 years after acute myocardial infarction in 35 streptoki .
nase- and 40 placebo-treated patients. The data displayed are only
from patients with complete follow-up (five radionuclide determina-
tions of
I
ft ventricular ejection fraction ILVEFI6
or. i n the early studies (3 days, 4 weeks), hemodynamic
instability or emergency bypass surgery . Ejection fraction
data from these 75 patients (Fig . I) were consistent with
results of analysis of ejection fraction data from all patients
(Table 2) . That is, there were differences in left ventricular
ejection fraction between the streptokinase and the placebo
group of 5% to 0% units (although these differences did not
reach statistical significance because of the smaller number
of patients in the latter group [0 .05 < p < 0 .25. respectively))
and differences of 11% to 14% units (p < 0 .02, respectively)
in patients with ar:terior myocardial infarction and no signif-
icant differences in patients with inferior myocardial infarc-
tion .
Intraindividual comparison of data obtained 3 days up to
3 years after acute myocardial infarction revealed the highest
values of left ventricular ejection fraction 7 months after
acute myocardial infarction in both treatment groups (Fig .
1)
. Whereas changes between the 5 determinations of left
ventricular ejection fraction did not reach statistical signifi-
cance in the streptokinase group (p > 0. 10, respectively), left
ventricular ejection fraction increased in the placebo group
from 4 weeks to 7 months after acute myocardial infarction
(p = 0
.02) .
Regional left ventricular function (Fig. 2)
.
In patients with
anterior myocardial infarction, regional left ventricular ejec-
tion fraction was reduced in most of the 13 sectors with
lower values in the placebo group during the total follow-up
period
. Compared with normal values, differences were
greatest in the apical wall and adjacent myocardium . Signif-
icant differences between the treatment and control groups
in < 0.05) occurred in the infarct area as well as in remote
myocardium and were most prominent 4 weeks after acute
myocardial infarction (Fig . 2A). In patients with inferior
myocardial infarction, regional left ventricular ejection frac-
tion was decreased in both the streptokinase and placebo
groups in apical and inferior walls as well as in the adjacent
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Figure
2
. Regional left ventricular ejection fraction lrLvffF)
weeks after acute anterior (A) or inferior (B) myocardial infarction .
A, 19 streptokinase-treated (while hays) and 24 placebo-treated
(hatched ban) patients . B, 28 streptokinase-treated (white hays) and
29 placebo-treated (latched bus) patients . Mean values
t
SEM are
shown
. Furcompanson with normal values from our Taboratory (17)
the area encompassing ± I standard deviation of the nomal talons
is shown between the thin lines . - p < 0.01 : - p < 0
.05 comparing
the streptokinase and placebo groups . ant .lat . = anterolateral .
ap . = apical ;tof. = inferior: post .lat. = posterolareral.
pans of the ta .^ :erolateral and paserolateral walls (Fig. 2B).
Compared with patients with anterior myocardial infarction,
among patients with inferior infarction differences between
the streptokinase and placebo groups were smaller and did
not reach statistical significance .
Analyzing only the data obtained from the 75 patients
with a complete follow-up concerning intraindividual com-
parison of regional left ventricular ejection fraction . signifi-
cant changes occurred only in sectors located within the
infarct zone with highest values 7 or 18 month~ after acute
infarction. Among patients with anterior myocardial infarc-
lion, regional left ventricular ejection fraction increased in
both treatment groups in one sector within the anteralateral
wall (p <_ 0.01 . respectively) and in the streptokinase group
in one additional sector within the apical waft (p =
(
.01)-
Among patients with inferior myocardial infarction, regional
left ventricular ejection fraction increased in both groups
within the posterolateml wall, in the streptokinase group is
VOTH FT At,
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one sector (p = 0.03) and in the placebo group in two sectors
(p < 0.001, respectively) .
Discussion
Global left ventricular function after streptokinase ther-
apy. The results of the present study using high dose short-
term intravenous streptokinase within 6 h after the onset of
symptoms o f acute myocardial infarction demonstrate a
benefit in left
ventricular function caused by early throm-
bolytic therapy . Three days after acute myocardial infarc-
lion, global left ventricular ejection fraction was 610 units
higher in the strcptokinase than in the placebo group (Table
2_). Because of the number of patients included in - 120) and
the to,, °requcncv of overall mortality (Table I), this benefit
in function
corm not be correlated with an improved sur-
vival (10 .19). Suoset analysis of ejection fraction data re-
vealed that the benefit for the total group is predominantly
caused by a benefit of about 10% units in ejection fraction in
patients with anterior myocardial infarction . Patients with
inferior myocardial infarction did not differ from control
patients . These results arc in good agreement with data
obtained by Res et al. (20) 2 days after intracoronary
administration of streptokinase with a benefit in global left
ventricular ejection fraction of 5% units in streptokinase .
treated patients with anterior myocardial infarction and an
insignificant difference of 1% unit in patients with inferior
myocardial infarction .
Anterior versus inferior inf^rclioh
. The difference be-
tween anterior and inferior myocardial infarction concerning
benefit in left ventticular function due to thrombolytic ther-
apy most likely can be attributed to the smaller size of
inferior compared with anterior infarcts 1211 . Benefit from
coronary reperfusion has been reported 12!
.222; to be greatest
in patients with a large infarct . Additional reasons for a
smaller or no benefit in patients with inferior infarction may
be a lower rate of intarct-related vessel patency and a higher
incidence of collateral vessels 123 .24). Furthermore, radio-
nuclide ventriculography in the left anterior ohtigne projec-
tion overestimates the contribution of the anterior myocar-
dial wall and underestimates the influence of the inferiorwall
because of photon absorption within the cardiac blood pool
(16)
.
Underestimation of global left ventricular ejection
fraction by 67r m 8% units by radionuclide ventriculography,
has been reported in patients with an ai .;c lnr-v=ll aneurysm
1161 and acute anterior myocardial infarction (25) .
However,
in acute inferior myocardial infarction. radionuclide deter-
mination of global left ventricular ejection fraction seems to
be less iufluc .r=ed by the wall motion abnoeemality . As
reported by Kennedy et al . (25). an overestimation of about
17, unit by radionuclide compared with contrast ventricu-
lography can be expected .
After reperfusion . formerly ischemic but nonnecrohc
myocardium requires several days to recover function (26) .
Previous studies (2-4) demonstrated an increase in global
left ventricular ejection fraction 2 to 3 weeks after acute
1614
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myocardial infarction . a time when most randomized trials of
intravenous streptokinase assessed left ventneuizr function
(7,27-30) . In accordance with our results (Table 2). a benefit
in ejection fraction of 6 % to 12% units was observed in
streptokinase-treated patients with anterior myocardial in-
farction. In inferior myocardial infarction, differences were
smaller (291 to 8% units) and a significant benefit was
observed only in some trials (27,30) .
Late follow-up results. Left ventricular function in pa-
tients treated by tbrombolysis has mostly been assessed only
within the lit year after acute myocardial infarction . Within
this period a stable benefit has been reported after intracor-
onary as well as after intravenous streptokinase (11-13,201 .
Data concerning longer follow-up periods are rare . Blanks et
al . (31) reported that ever 3 years patients treated by
intracoronary streptokinase had a benefit in left vertricular
function compared with results in a ronraadomized control
group . The findings of the present study-a benefit in left
ventricular function in the streptokinase-treated group 3
days after acute myocardial infarction (Table 2) and stability
of global left ventricular ejection fraction in this group up to
3 years (Fig . t)--confirm these data with respect to intrave-
nous streptokinase . Thus, we found that intravenous strep-
tokinase results in a benefit in global left ventricular function
that is preserved at least up to 3 years pier acute myocardial
infarction .
In contrast to our streptokinase group, there was a slight
increase in global left ventricular ejection fraction in the
placebo group from 4 weeks to 7 months after acute myo-
cardial infarction (Fig. 1) . Schelbert et al . (32) similarly
observed an ircrase in global left ventricular ejection
fraction in 61% if conventionally treated patients in the late
postinfarctton pried
. The presence of ischemic but viable
myocardium in the infarct area (33) recovering as a result of
development of collateral channels, or late reperfusion, or
functional improvement of noninfarcted myocardium (8,34)
may explain this finding.
Regional left ventricular function, Determiraticn of global
left ventricular ejection fraction is trot the mist effective way to
assess the effects of thrembolysis within the infarct area.
Evaluation of regiorsl myocardial function has been reported
(8,35) to be more sensitive since dysfunction of the infarct area
may be superimposed by hypsekinesia of remote myocardium.
In the present study, t egional left ventricular ejection fraction
was higher in the infarct area as well as in remote myocardium
in patients with anterior myocardial infarction in the streptoki
ease group than in such patients in the placebogroop (Fig
. 2A).
This finding was demonstrable from 3 days up to 3 years after
acute infarction. Four weeks after anterior myocardial infarc-
tion, Serruys et al
. (8) also observed differences between
treatment and control groups in both infarcted and nonin-
fardted areas. Martin et al. (23) and Bassand et al
. (29) reported
differences only in remote myocardium. Treatment versus
control group differences with respect to infarct area are best
explained by limitation of infarct size due to early reperfusion
IACC vo 18 . Nu . 7
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(36,37) . whereas differences with respect to remote areas may
have several mechanisms
. In experimental mfarction, focal
myocardial necrosis and metabolic licrant'emenls indicating
schema have been observed in nono•.duded segments 138) .
These findings were mole evident with permanent occlusion
than with reperfusion alter 3 hours of ecciusion (38) . 'two
weeks after acute myocardial infarction, Martin et al . (23)
observed mild hyperkinesia of nonitd'aretnd myocardium in
Fteptokinase-treated patients but not in randomized control
patients. This phenomenon was more marked in patients with
tan!tivessel disease than in those with single-vessel disease .
Martin et al . (23) attibuted their findings to the higher rte of
infarct-related vessel patency in streptokintu°-treated patients
.
resulting in additional blood flow to noninfarcied ar ` .as from the
patent infarct vessel as a result of collateral flow .
In contrast to patients with anterior myocardial i^ :ar.--
tion, among patients with inferior infarction, no differences
between the two treatment groups were demonstrable in the
present study (Fig. 2B) . This result is it, accordance with
data from similar studies also using radionuclide ventricu-
lography (28,29) . However, the majority of trial .. (3,14,34)
employing contrast angiography demonstrated minor dys-
function of the infarct zone in streptokinase- compared
with
placebo treated patients . The discrepancy between results
obtained with radionuclide and contrast ventriculograplty,
may be explained cy the higher spatial resolution of the
contrast technique and by the difficulty of assessing the
inferior myocardiai wall by radionuclide determination of
regional left ventricular ejection fraction, even when biplane
radionuclide ventriculagaphy is used (17) .
In previous studies, serial analysis of regional left ven-
tricular function after thrombolysis has been performed up
to 6 months after acute myocardial infarction t :. 4,24,26 .35) .
After early reperfusion, improvement of regional wall too-
tion s
.'
:hin the infarct area was observed beginning 3 days
after infarction (26) . In the present study we analyzed
regional left ventricular ejection fraction from 3 days to 3
years after acute infarction . During this period, areas with an
increase of regional left ventricular ejection fraction were
observed in both treatment groups within the infarct zone
with the highest values 7 or 18 months after infarction
. In
noninfarct d areas, regional lilt ventricular ejection fraction
did not change significantly
. After coronary artery bypass
surgery, Serruys et al. (34) reported an increase of the
initially depressed regional shortening fraction in bypassed
and nonbypassed regions up to 6 months postoperatively,
They attributed this finding to recovery of myocardium from
an ischemic Injury, a thesis that would also explain the
increase is regional left ventricular ejection fraction within
the infarct zone observed in the present study
.
Limitations of the study. The major limitation of the
present study is the high degree of incomplete follow-up,
which may influence longitudinal analysis . Although radio-
nuclide ventriculographic studies were performed in 84% a°
all patients included or 91% of patients alive at the time of
investigation._ complete follow-up was available in only 75
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